A prospective study on tumour response assessment methods after 1 neoadjuvant endocrine therapy in early oestrogen receptor positive breast 2 cancer 3 4 **Running title:** Tumour response after neoadjuvant endocrine therapy in early 5 ER positive breast cancer Joanna I. López-Velazco<sup>1\*</sup>, Sara Manzano<sup>1\*</sup>, María Otaño<sup>2</sup>, Kepa Elorriaga<sup>2</sup>, 6 Núria Bultó<sup>2</sup>, Julio Herrero<sup>2</sup>, Ainhara Lahuerta<sup>1,2</sup>, Virginia Segur<sup>2</sup>, Isabel 7 Álvarez-López<sup>1,2</sup>, Maria M. Caffarel<sup>1,3#</sup> and Ander Urruticoechea<sup>1,2#</sup> 8 9 <sup>1</sup> Biodonostia Health Research Institute, San Sebastian, Spain. <sup>2</sup> Gipuzkoa 10 Cancer Unit, OSI Donostialdea - Onkologikoa Foundation, San Sebastian, 11 Spain. <sup>3</sup> IKERBASQUE, Basque Foundation for Science, Bilbao, Spain. 12 \*These authors share first authorship. #These authors share senior and 13 14 corresponding authorship. <sup>#</sup> Corresponding authors: Dr Maria M. Caffarel, Biodonostia Health 15 Research Institute, Paseo Dr Begiristain s/n, San Sebastian, 20014, Spain. 16 Email: maria.caffarel@biodonostia.org, Tel: +34 943328193. // Dr Ander 17 Urruticoechea, Onkologikoa Foundation, Paseo Dr Begiristain 121, San 18 Sebastian, 20014, Spain. Email: anderu@onkologikoa.org, Tel: +34 19 943328400. 20 21 **Conflict of interest:** The authors have declared that no conflict of interest exists. 22 23

Word count (Introduction to discussion): 3446

24

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

#### 25 Abstract

Neoadjuvant endocrine therapy (NET) in oestrogen receptor-positive/HER2-26 negative breast cancer (ER+/HER2- BC) allows real-time evaluation of drug 27 28 efficacy and biological changes upon estrogenic deprivation. Clinical and pathological evaluation after NET may be used to obtain prognostic and 29 predictive information of tumour response. Scales developed to evaluate 30 response after neoadjuvant chemotherapy are not useful and there are not 31 32 many validated biomarkers to assess response to NET. In this prospective study, we analysed radiological and pathological tumour response of 104 33 34 postmenopausal ER+/HER2- BC patients, treated with NET for a mean of 7 months. Our results show that radiological evaluation underestimates 35 36 pathological tumour size, although it can be used to assess tumour response. In 37 addition, we propose that the tumour cellularity size (TCS), calculated as the product of the residual tumour cellularity in the surgical specimen and the 38 tumour pathological size, could become a new tool to standardize response 39 assessment to NET. It is simple, reproducible and correlates with the existing 40 biomarkers. Our findings shed light on the dynamics of NET response, 41 challenge the paradigm of the ability of NET to decrease surgical volume and 42 point to the utility of the TCS to quantify the scattered tumour response usually 43 produced by endocrine therapy. 44

Keywords: Neoadjuvant endocrine therapy, aromatase inhibitors, tumour
cellularity size, oestrogen receptor (ER) positive breast cancer, pathological and
radiological tumour response, preoperative endocrine prognostic index (PEPI)
score, Ki67.

2

#### 49 Background

Oestrogen receptor positive (ER+)/human epidermal growth factor receptor 2 50 negative (HER2-) breast cancer (hereafter referred to as ER+ BC) represents 51 52 almost 70% of all breast malignancies. Antiestrogenic or endocrine therapy is the cornerstone of ER+ BC treatment, being the neoadjuvant (preoperative) 53 54 setting a very attractive scenario to find novel biomarkers of response and therapeutic strategies<sup>1</sup>. This is an urgent clinical need because long-term 55 resistance to endocrine therapy is a common event<sup>1</sup>. Neoadjuvant endocrine 56 therapy (NET) results in pathological and clinical response rates similar to those 57 58 observed with neoadjuvant chemotherapy (NCT) although with lower toxicity<sup>2,3</sup>. Three pioneer clinical trials (IMPACT, PROACT and P024) demonstrated that 59 60 NET is effective in downsizing ER+ BC and facilitating breast-conserving surgery (BCS) and showed greater efficacy for aromatase inhibitors compared 61 with tamoxifen<sup>4–6</sup>. As a consequence of these and other studies, NET, given for 62 4-8 months, is nowadays recommended by international guidelines for 63 postmenopausal women presenting ER+ BC<sup>7-9</sup>. An important advantage of NET 64 is that it allows "in vivo" evaluation of response, hence granting real-time 65 examination of drug efficacy as well as investigation of the biological and 66 molecular changes that occur after estrogenic deprivation. However, the lack of 67 useful biomarkers of long-term efficacy of therapy has precluded the 68 development of the neoadjuvant strategy for endocrine therapies. 69

70 In the management of patients under neoadjuvant systemic therapy (either NET or NCT) two important evaluations are performed. First, a preoperative 71 72 assessment of radiological tumour response (rad-TR) determines the response grade and establishes the surgical strategy<sup>10–12</sup>. Next, surgical specimens are 73 74 histopathologically evaluated to obtain prognostic information according to pathological tumour response (path-TR) scales<sup>10,12</sup>. In the case of BC patients 75 treated with NCT, there are well-stablished parameters to measure tumour 76 response, such as RECIST criteria, Miller & Payne and Sataloff grading scales, 77 and residual cancer burden value<sup>13–16</sup>. However, only Preoperative Endocrine 78 Therapy Prognostic Index (PEPI) score and Ki67 levels have been validated as 79 prognostic markers after NET<sup>17–19</sup>. Hence, tumours that show substantial down-80 staging after NET and present low Ki67 levels and PEPI score at surgery have 81

an excellent long-term prognosis even without chemotherapy<sup>1,11,19,20</sup>. Both Ki67 82 83 levels after NET and PEPI score have been shown to predict long-term outcomes (e.g., relapse-free survival). However, they are not optimal and they 84 are not routinely used due to, among other reasons, a lack of Ki67 85 measurement standardisation<sup>21</sup>. In the clinical practice, understanding the 86 impact of tumour response to NET in long-term outcome will help clinicians to 87 individualize adjuvant treatment for ER+ BC. In contrast to what happens for 88 NCT, pathologic complete response (pCR) after NET is a rare event and is not 89 a useful marker of prognosis given its low likelihood<sup>3,17,22</sup>. In fact, previous 90 studies suggest that ER+ BC tumours after neoadjuvant systemic therapy 91 92 present a "diffuse cell loss" response at pathological level, which is characterized by a distribution of the tumour in multiple scattered foci or small 93 groups of tumour cells without affecting overall tumour size<sup>23</sup>. 94

In this context, there is an urgent need for the identification of robust, 95 reproducible biomarkers of response to NET with long term prognostic value. 96 Ideally, these new biomarkers should be candidates for initial validation in 97 retrospective series. In addition, the mentioned diffuse cell loss in ER+ BC 98 patients treated with NET needs to be better characterized. In order to 99 investigate the dynamics of tumour response, we generated a prospectively 100 collected series of ER+ BC patients treated with NET. We characterised and 101 compared tumour response by ultrasound scan (USS) and/or magnetic 102 103 resonance imaging (MRI) with pathological tumour size (path-TS). Finally, we 104 described a new biomarker with potential prognostic implications, called tumour cellularity size (TCS), which could help to characterize the response to NET in 105 106 ER+ BC by an estimation of the diffuse cell loss.

4

#### 107 Methods

#### 108 Study population

109 We analysed clinical data from a cohort of patients treated in our institution 110 between 2005 and 2019 following a homogenous therapeutic protocol. Data 111 prospectively collected and retrospectively analysed. All were were postmenopausal women with histologically confirmed, untreated, invasive, 112 113 operable, larger than 10 mm and amenable for radiological follow-up, ER+/HER2- non-metastatic breast cancer. Patients had to be treated for at least 114 115 3 months with NET prior to surgery with curative intention. The administered NET was an aromatase inhibitor except contraindicated. Informed consent was 116 obtained from all patients. 117

### 118 Imaging and histopathological analysis

Tumour baseline assessment was performed by breast USS and/or MRI. 119 120 Clinical response by USS was evaluated after 2 months of treatment and repeated every 2 months. MRI and/or USS were also performed before surgery 121 122 to evaluate radiological tumour response (rad-TR). Surgical breast specimens were evaluated by the pathologist to determine pathological tumour response 123 124 (path-TR), tumour size (path-TS) and residual tumour cellularity (%). Clinical (assessed by MRI and USS) or pathological tumour size corresponds to the 125 major diameter of the tumour in millimetres (mm) and T-stage of the primary 126 tumour was defined according to AJCC Cancer Staging Manual<sup>24</sup>. 127

Immunohistochemistry analyses were performed in baseline formalin-fixed 128 paraffin-embedded biopsies and surgical specimens to determine the 129 130 expression of ER, progesterone receptor (PgR) and Ki67 levels, using international standards<sup>25,26</sup>. ER, PgR and Ki67 were recorded as continuous 131 variables. The positivity cut-off for ER and PgR was ≥10% of stained nuclei. 132 Ki67 score was defined as the percentage of tumour cells with Ki67 positive 133 nuclear staining. At least 1000 tumour nuclei were counted per sample, 134 according to the recommendations of Dowsett et al., 2011<sup>25</sup>. The change in 135 136 Ki67 ( $\Delta$ Ki67) after NET was calculated using the following equation:  $\Delta$ Ki67 = [(Ki67 (%) in surgery specimen) – (Ki67 (%) in baseline biopsy)] / (Ki67 (%) in 137 baseline biopsy). Consequently,  $\Delta$ Ki67 values ranged between -1 to 1.  $\Delta$ Ki67 138

results were categorized into three groups depending on their magnitude of change.  $\Delta$ Ki67 = -1 means that Ki67 changes to zero in the surgery specimen.  $\Delta$ Ki67 = > -1 to < 0 means that the tumour presented a decrease in Ki67 expression. Finally,  $\Delta$ Ki67 ≥ 0 means that the tumour did not present any change in Ki67 expression or that Ki67 expression in the surgery specimen was greater than the one on baseline biopsy.

Rad-TR was defined using mRECIST 1.1 criteria<sup>13</sup>. According with this criteria, complete responses (CR) were defined as tumour disappearance and partial responses (PR) were defined as the reduction of the tumour diameter by  $\geq$  30%. An increase  $\geq$  20% in tumour diameter was qualified as progressive disease (PD). The rest of situations were qualified as stable disease (SD).

Path-TR was quantified using a modified Miller and Payne grading scale<sup>14,27</sup>. In this scale, response grades 1 and 2 (no change or less than 30% loss of tumour cells, respectively) were regarded as SD. Grades 3 and 4 (reduction in tumour cells between 30-90% and > 90%, respectively) were considered as pathologic PR. Grade 5 (defined as no malignant cells identifiable in the tumour niche) was considered pathologic CR (pCR). In binary analyses, path-TR was defined as loss of tumour cells  $\geq$  30 % (grades 3-5) and no path-TR as <30% (grades 1-2).

Modified PEPI (mPEPI) score was determined on the basis of tumour characteristics of surgical specimen (i.e. tumour size, nodal involvement status and Ki67 staining), as previously published<sup>18,28</sup>. Patients were classified into 3 mPEPI risk groups (I=0, II=1-3 and III=4+).

161 TCS, the novel score we introduce in this study, was calculated as the product 162 of tumour cellularity in the surgical sample (%) and tumour diameter (path-TS, 163 in mm).

#### 164 **Statistical analyses**

165 Statistical analyses were performed using GraphPad Prism version 9. For the 166 descriptive statistical analyses, minimum, maximum and mean values were 167 used. For Gaussians distributions, paired Student's t-test was used to compare 168 differences between two groups. For non-Gaussian distributions, Wilcoxon 169 matched-pairs or Kruskal-Wallis tests were performed. Chi-square or Fisher's 170 tests were used to determine differences between expected frequencies.

- 171 Spearman's r coefficient (rho) for analyses, were used to quantify correlations
- 172 (both with a 95% of confidence interval). P values < 0.05 were considered
- 173 statistically significant. Unless otherwise specified, histograms represent mean
- values +/- standard error of the mean (SEM).

## 175 **Results**

#### 176 **Tumour characteristics and change in tumour biomarkers after NET**

177 104 patients with early ER+/HER2 breast cancer were included in our study. 178 The study population presented a mean age at diagnosis of 69 (47-93) years 179 and the mean NET duration before surgery was 7 months (3-39). The mean tumour size was 25 mm (10-90) assessed by MRI and 18 mm (40-70) by USS. 180 181 The main administered NET drug was letrozole (n=100), but some patients also received anastrozole (n=2), tamoxifen (n=1), or exemestane (n=1). One patient 182 was diagnosed with bilateral disease and her two tumours were independently 183 considered in our analyses. The principal characteristics of the tumours and 184 their surgical management as well as the pathological changes after NET are 185 186 summarised in Table 1. No significant decrease of histological grade was observed after NET (p = 0.12). Ki67, ER and PgR expression was assessed in 187 all tumours pre- and post- NET treatment. As seen in previous studies using 188 similar cohorts (Toi et al. 2011; Martí et al. 2022), NET significantly decreased 189 all these three parameters, being the changes in Ki67 and PgR the most 190 significant (both p < 0.0001, Table 1 and supplementary material, Figure S1). 191 While only 13 patients (12%) were cN+ before treatment, 26 patients (25%) 192 were pN+ at pathological assessment. Regarding pathological tumour response 193 194 to NET, only one case of pCR was recorded and most cases (72%) showed partial path-TR (Table 2). Most patients (81%) fell into low (I, n=34, 35%) and 195 196 intermediate (II, n=45, 46%) mPEPI risk groups. These results are in agreement with the response rates obtained in similar series<sup>8,10,12</sup>. 197

# Radiological examination of tumour size after NET underestimates pathological tumour size

To determine which is the best radiological technique to predict pathological tumour size (path-TS) after NET, we compared tumour size measured by MRI and USS before and after treatment. As expected, radiological tumour size (rad-TS), measured by MRI or USS, both at diagnosis and after NET (just before surgery), significantly correlated with path-TS (Figure 1A-D). Surprisingly, our results showed that path-TS correlated better with tumour size assessed by MRI and USS at diagnosis than after NET (Figure 1A). This may suggest that

the radiological evaluation before surgery may not be a very precise technique 207 to assess tumour size after NET. To better visualize this, we compared the 208 209 mean value of tumour size assessed by each radiological technique, before and after NET, and by path-TS. As shown in Figure 1E, MRI/USS measurements 210 after NET were significantly lower than path-TS and, interestingly, radiological 211 measures at diagnosis were more similar to path-TS than the measures after 212 treatment. Actually, MRI and USS before surgery underestimated path-TS in 213 77% (76/99) and 92% (84/91) of the cases, respectively. 214

Importantly, we also found that this disagreement in tumour size estimation by 215 216 imaging and histopathological analysis affects the concordance between radiological (rad-TR) and pathological (path-TR) tumour response (Table 2). 217 218 Complete rad-TR was observed in 27 (by MRI) and 16 (by USS) patients while only one patient presented a pCR by pathological assessment. To better 219 visualize these discrepancies, we plotted the correlation between rad- and path-220 221 TR. As shown in Figure 2A-B, we found that rad-TR assessed by MRI correlated better with path-TR than rad-TR assessed by USS, although both 222 associations were statistically significant. Interestingly, we observed that a 223 considerable number of tumours presented a complete (100%) rad-TR after 224 NET but presented a low path-TR (G2 or G3, highlighted in red in Figure 2A-B). 225 Taken together, our data indicate that the radiological examination of tumour 226 size after NET and before surgery underestimates path-TS bearing surgical 227 implications for the definition of tumour area. 228

Next, we evaluated the association between rad- and path-TR with the two most accepted prognostic markers after NET: Ki67 levels and mPEPI score<sup>11,18,28</sup>. As expected, pathological responders presented significantly lower Ki67 levels at surgery and mPEPI score (Figure 2C-D). Regarding rad-TR, both prognostic markers were associated with tumour response assessed by MRI (Figure 2E-F), but, in the case of USS, there was not association between tumour response and Ki67 and PEPI score (Figure 2G-H).

In summary, our data support that radiological evaluation of tumour size after
 NET underestimates pathological tumour size and indicate that MRI could be
 more reliable than USS to assess response to NET.

# Tumour cellularity size is a new parameter to standardize the assessment of residual tumour content after NET

241 Diffuse cell loss has been observed as a common pattern of tumour response after neoadjuvant therapies in ER+ (luminal) tumours<sup>23</sup>. In an attempt to better 242 assess tumour response after NET, we propose a novel parameter called 243 244 tumour cellularity size (TCS). TCS is the product of tumour cellularity (%) and 245 tumour diameter (path-TS, in mm) and estimates the volume of remaining cells 246 in the tumour bed after NET. First, we evaluated how TCS relates to radiological tumour size and response (Figure 3). As seen in Figure 3A, TCS values were 247 248 much lower than path-TS and more similar to MRI or USS measures after NET compared to rad-TS at diagnosis or path-TS. We then analysed how TCS 249 250 associates with radiological and pathological response (Figure 3B-D). Our results showed that TCS inversely correlated with path-TR and with MRI rad-TR 251 (Figure 3B-C). However, the association between TCS and rad-TR determined 252 253 by USS was not significant (Figure 3D), in line with previous results supporting that MRI may be more adequate than USS to quantify response to NET. Taken 254 together, our data indicate that TCS can quantify the tumour "diffuse cell loss" 255 response observed in ER+ BC tumours after NET, and may capture better the 256 257 biological response of those tumours and explain why the radiological preoperative assessment of tumour size underestimates the path-TS. 258

In order to further evaluate if TCS can be used as a biomarker of response and 259 260 prognosis for patients undergoing NET, we evaluated its association with changes in Ki67 ( $\Delta$ Ki67) (Figure 3E-G) and Ki67 levels at surgery 261 (supplementary material, Figure S2), well-established prognostic markers after 262 NET. We observed that  $\Delta$ Ki67 and Ki67 expression at surgery correlated better 263 264 with TCS than with tumour cellularity or path-TS (Figure 3E-G, and 265 supplementary material, Figure S2A-C). Consequently, tumours with high residual Ki67 expression ( $\Delta$ Ki67 > 0 and high Ki67 expression at surgery) also 266 present a high TCS, suggesting that TCS could be a promising biomarker of 267 268 response to NET.

Finally, to identify an initial cut-off value for which TCS can divide patients responding to NET from no responder patients, we analysed the relationship of TCS quartiles with Ki67 (Figure 4 and supplementary material, Figure S3A-B).

As mentioned before, TCS is positively correlated with Ki67 at surgery and  $\Delta$ Ki67 (Figure S3). Tumours with TCS <2.5 mm (Q1) showed significantly lower Ki67 levels at surgery and  $\Delta$ Ki67 compared with tumours with TCS  $\geq$  2.5 mm (Q2, Q3 and Q4, Figure 4), suggesting that a TCS value <2.5 mm could be used as a good cut-off value to identify patients responding to NET. However, more studies in independent cohorts with associated survival data are needed.

#### 278 Discussion

There are different reasons why neadjuvant endocrine therapy (NET) is a very 279 promising and attractive therapeutic strategy for ER+ BC patients. First, it is less 280 281 toxic than neoadjuvant chemotherapy albeit resulting in similar pathological and clinical response rates and, indeed, it is already recommended by international 282 guidelines for post-menopausal women<sup>3</sup>. Finally, it represents an ideal scenario 283 for clinical research as it allows real time investigation of drug efficacy and of 284 285 the molecular and biological changes in tumours after endocrine treatment. This may lead to the identification of novel biomarkers of response and new 286 287 therapeutic strategies. However, NET remains an underused tool for ER+ BC because monitoring response is challenging, among other reasons<sup>3,29</sup>. Many 288 289 NET clinical trials use the radiological response rate (by pre-operative evaluation with USS, mammography or MRI using RECIST 1.1 criteria) and 290 improvement of BCS rates as a primary objective to demonstrate 291 effectiveness<sup>3,11,12</sup>. However, our results, obtained from a prospectively 292 293 collected series of 104 ER+ BC patients treated with NET, prove that the preoperative radiological evaluation after NET underestimates path-TS. Previous 294 reports have also shown that radiological and clinical evaluation after NET 295 underestimate the lesion size<sup>10</sup>, although Reis and cols found this difference 296 negligible<sup>30</sup>. Clinically, 297 these discrepancies between radiological and pathological responses may have strong surgical implications for the definition 298 of lesion area and our data suggest that the radiological evaluation of tumour 299 300 size should not be determinant to plan the resection area. In fact, the AJCC recommends that imaging findings after NET, NCT and radiotherapy are not 301 considered elements of initial clinical staging<sup>24</sup>. 302

303 In addition, our data show that radiological complete responses almost never 304 parallel pCR. In our series, 26% and 15% of patients showed complete 305 radiological response by MRI and USS, respectively, but only 1 patient achieved pCR. In fact, pCR after NET is a rare event and only occurs in less 306 than 1% of the cases<sup>3</sup>. Usually, residual disease is found even in very good 307 responder tumours, in the form of microscopically scattered residual cancer 308 nests in the tumour bed [30]. This scattered or diffuse cell loss response is also 309 observed after neoadjuvant chemotherapy in ER+ tumours<sup>23</sup>. 310

12

While pathological assessment considers the maximum area occupied by the 311 312 tumour and does not capture this scattered response, radiological evaluation after NET may reflect the diffuse cell loss response. This could explain why rad-313 TS after NET did not reflect path-TS in the surgery specimens in our cohort and 314 challenges the paradigm of NET as a tool to increase the BCS rates for ER+ 315 BC. The difference between radiological and pathological evaluation of 316 neoadjuvant systemic treatment (NST) is less frequently observed in triple-317 negative and non-luminal HER2+ tumours, which tend to present a shrinkage or 318 concentric response (also called tumour collapse) to NST<sup>23</sup>. 319

Nevertheless, we should also take into consideration that the complete response assessed by MRI may capture biological events with potential prognostic/predictive value, including normalization of tumour vessels. Hence, the event of CR by MRI, even without pCR, may define a prognostic category that deserves further study.

Despite the discrepancies between radiological and pathological evaluation of 325 tumour response to NET, clinical and radiological monitoring of tumour 326 327 response during the course of NET are necessary to early detect disease 328 progression. Our data indicate that MRI is preferable than USS to assess response to NET, as 1) path-TR correlated better with rad-TR assessed by MRI 329 330 than by USS and 2) MRI rad-TR was significantly associated with reduction of Ki67 in the surgical specimen and lower mPEPI score, the two most accepted 331 prognostic markers after NET<sup>11,18,28</sup>. This association was not statistically 332 significant in the case of USS. Our results are in agreement with previous 333 reports supporting the use of MRI as the most accurate tool among other 334 335 methods (clinical examination, USS and mammography) to assess tumour response to NST in breast cancer<sup>3,31</sup>. 336

As mentioned above, the diffuse cell loss response observed in ER+ tumours as a response to NST represents a challenge to evaluate tumour response to NET. We hypothesize that the parameter tumour cellularity size (TCS), presented herein, can be used to assess the scattered response to NET as it estimates the multiple scattered foci of tumour cells in the tumour niche. TCS is the product of tumour cellularity (%) and tumour diameter (path-TS, in mm) in the post-treatment surgical sample. We found that TCS significantly associated

with rad-TR evaluated with MRI. As previously discussed, only PEPI score and 344 Ki67 expression under treatment are validated prognostic markers for NET<sup>17–19</sup>. 345 Importantly, TCS correlated better with  $\Delta$ Ki67 than the percentage of tumour 346 cellularity in the post-treatment sample and the path-TS. This may indicate that 347 reduction in Ki67 expression is related to the tumour cellularity content even 348 when the path-TS does not change after NET. The association between TCS 349 and mPEPI score could not be evaluated as they are not independent variables 350 351 since both include path-TS in their calculation<sup>28</sup>.

In summary, our results shed light on two clinically relevant and unanswered 352 353 questions in the context of NET highlighted by Sella and cols<sup>3</sup>. One of them is which is the optimal imaging technique to pre-surgically evaluate residual 354 355 disease after NET. Our data supports the use of MRI over USS, but also prove 356 that both imaging techniques underestimate pathological tumour size. As mentioned, this points to careful consideration of clinical and radiological TR to 357 define the surgical resection tumour area and challenge the paradigm of the 358 reduction of surgical volume by NET given that the initial radiological 359 assessment seems to be the best value to define the tumour area even after 360 therapy. The second unanswered question is the need of novel biomarkers to 361 assess pathological response to NET. We propose a new biomarker called 362 363 tumour cellularity size (TCS) that could be a promising candidate to use in combination with changes in Ki67, although it should be validated in larger 364 cohorts. 365

### 366 Additional information

367 Supplementary information is available at BJC's website

### 368 Acknowledgements

We are grateful to the members of our laboratory for critical discussion of this work and to the Pathology Services of Hospital Donostia and Onkologikoa Foundation for technical assistance.

## 372 Ethics Approval

The study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines as well as authorised by the Spain Health Authority and the local Ethics Committee.

## 376 Authors' contributions

JILV, SM, AU and MMC analysed the data and wrote the manuscript. AU designed the study. AU and MMC co-supervised the study. KE analysed histopathology. VS and NB analysed imaging data. JILV, MO, AL, JH, IAL and AU collected and analysed patient data.

## 381 Funding

This work was funded by Instituto de Salud Carlos III (ISCIII) grants: PI21/01208, PI20/01253, CP18/00076 and FI19/00193 co-funded by the European Union, Basque Department of Health (2020111040), Fundación SEOM (SEOM Avon Fellowship 2020) and Ikerbasque Basque Research Foundation. The group also received funds from the breast cancer patient's charity Katxalin and from Roche Farma S.A. JILV is funded by an AECC PhD Fellowship (PRDGI19007LOPE).

## 389 Data availability statement

The data for this study are available upon reasonable request.

## 391 **Consent for publication and competing interests**

We verify that each author consents the publication of this manuscript and authors have no conflicts of interest to declare.

#### 394 **REFERENCES**

- Burstein, H. J. Systemic Therapy for Estrogen Receptor–Positive, HER2 Negative Breast Cancer. *N. Engl. J. Med.* 383, 2557–2570 (2020).
- 2. Spring, L. M., Gupta, A., Reynolds, K. L., Gadd, M. A., Ellisen, L. W.,
- Isakoff, S. J. et al. Neoadjuvant endocrine therapy for estrogen receptorpositive breast cancer a systematic review and meta-Analysis. *JAMA Oncol.* 2, 1477–1486 (2016).
- Sella, T., Weiss, A., Mittendorf, E. A., King, T. A., Pilewskie, M., Giuliano,
   A. E. et al. Neoadjuvant Endocrine Therapy in Clinical Practice: A Review.
   *JAMA Oncol.* 7, 1700–1708 (2021).
- 404 4. Eiermann, W., Paepke, S., Appfelstaedt, J., Llombart-Cussac, A., Eremin,
   405 J., Vinholes, J. et al. Preoperative treatment of postmenopausal breast
   406 cancer patients with letrozole: A randomized double-blind multicenter
   407 study. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 12, 1527–1532 (2001).
- 5. Cataliotti, L., Buzdar, A. U., Noguchi, S., Bines, J., Takatsuka, Y.,
- 409 Petrakova, K. et al. Comparison of anastrozole versus tamoxifen as
- 410 preoperative therapy in postmenopausal women with hormone receptor-
- 411 positive breast cancer: the Pre-Operative "Arimidex" Compared to
- 412 Tamoxifen (PROACT) trial. *Cancer* **106**, 2095–2103 (2006).
- 413 6. Smith, I. E., Dowsett, M., Ebbs, S. R., Dixon, J. M., Skene, A., Blohmer,
- J.-U. et al. Neoadjuvant treatment of postmenopausal breast cancer with
- anastrozole, tamoxifen, or both in combination: the Immediate
- 416 Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen
  417 (IMPACT) multicenter double-blind randomized trial. *J. Clin. Oncol. Off. J.*
- 418 Am. Soc. Clin. Oncol. 23, 5108–5116 (2005).
- Korde, L. A., Somerfield, M. R., Carey, L. A., Crews, J. R., Denduluri, N.,
  Hwang, E. S. et al. Neoadjuvant Chemotherapy, Endocrine Therapy, and
  Targeted Therapy for Breast Cancer: ASCO Guideline. *J. Clin. Oncol.* 39,
  1485–1505 (2021).
- 423 8. Martí, C., Yébenes, L., Oliver, J. M., Moreno, E., Frías, L., Berjón, A. et al.
  424 The Clinical Impact of Neoadjuvant Endocrine Treatment on Luminal-like

425 426		Breast Cancers and Its Prognostic Significance: Results from a Single- Institution Prospective Cohort Study. <i>Curr. Oncol.</i> <b>29</b> , 2199–2210 (2022).
427 428 429 430	9.	Cardoso, F., Kyriakides, S., Ohno, S., Penault-Llorca, F., Poortmans, P., Rubio, I. T. et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Ann. Oncol. Off. J. Eur. Soc.</i> <i>Med. Oncol.</i> <b>30</b> , 1674 (2019).
431 432 433 434 435 436	10.	Lerebours, F., Rivera, S., Mouret-Reynier, M. A., Alran, S., Venat-Bouvet, L., Kerbrat, P. et al. Randomized phase 2 neoadjuvant trial evaluating anastrozole and fulvestrant efficacy for postmenopausal, estrogen receptor–positive, human epidermal growth factor receptor 2–negative breast cancer patients: Results of the UNICANCER CARMINA 02 french trial. <i>Cancer</i> <b>122</b> , 3032–3040 (2016).
437 438 439 440	11.	Ueno, T., Saji, S., Masuda, N., Kuroi, K., Sato, N., Takei, H. et al. Impact of clinical response to neoadjuvant endocrine therapy on patient outcomes: A follow-up study of JFMC34-0601 multicentre prospective neoadjuvant endocrine trial. <i>ESMO Open</i> <b>3</b> , (2018).
441 442 443 444 445	12.	Skriver, S. K., Laenkholm, A. V., Rasmussen, B. B., Handler, J., Grundtmann, B., Tvedskov, T. F. et al. Neoadjuvant letrozole for postmenopausal estrogen receptor-positive, HER2-negative breast cancer patients, a study from the Danish Breast Cancer Cooperative Group (DBCG). <i>Acta Oncol. (Madr).</i> <b>57</b> , 31–37 (2018).
446 447 448 449	13.	Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R. et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). <i>Eur. J. Cancer</i> <b>45</b> , 228–247 (2009).
450 451 452 453	14.	Ogston, K. N., Miller, I. D., Payne, S., Hutcheon, A. W., Sarkar, T. K., Smith, I. et al. A new histological grading system to assess response of breast cancers to primary chemotherapy: Prognostic significance and survival. <i>Breast</i> <b>12</b> , 320–327 (2003).
454 455 456	15.	Sataloff, D. M., Mason, B. A., Prestipino, A. J., Seinige, U. L., Lieber, C. P. & Baloch, Z. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. <i>J. Am.</i>

## 457 *Coll. Surg.* **180**, 297–306 (1995).

Symmans, W. F., Wei, C., Gould, R., Yu, X., Zhang, Y., Liu, M. et al. 16. 458 459 Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated 460 With Residual Cancer Burden and Breast Cancer Subtype. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 35, 1049-1060 (2017). 461 Lerebours, F., Pulido, M., Fourme, E., Debled, M., Becette, V., Bonnefoi, 17. 462 463 H. et al. Predictive factors of 5-year relapse-free survival in HR+/HER2breast cancer patients treated with neoadjuvant endocrine therapy: 464 pooled analysis of two phase 2 trials. Br. J. Cancer 122, 759–765 (2020). 465 18. Suman, V. J., Ellis, M. J. & Ma, C. X. The ALTERNATE trial: Assessing a 466 biomarker driven strategy for the treatment of post-menopausal women 467 with Er+/Her2- invasive breast cancer. Chinese Clinical Oncology vol. 4 468 (2015). 469 Guarneri, V., Dieci, M. V., Bisagni, G., Frassoldati, A., Bianchi, G. V., De 470 19. Salvo, G. L. et al. De-escalated therapy for HR+/HER2+ breast cancer 471 472 patients with Ki67 response after 2-week letrozole: Results of the PerELISA neoadjuvant study. Ann. Oncol. 30, 921-926 (2019). 473 Smith, I., Robertson, J., Kilburn, L., Wilcox, M., Evans, A., Holcombe, C. 474 20. et al. Long-term outcome and prognostic value of Ki67 after perioperative 475 endocrine therapy in postmenopausal women with hormone-sensitive 476 early breast cancer (POETIC); an open-label, multicentre, parallel-group. 477 randomised, phase 3 trial. Lancet Oncol. 21, 1443-1454 (2020). 478 Ellis, M. J., Suman, V. J., Hoog, J., Goncalves, R., Sanati, S., Creighton, 479 21. C. J. et al. Ki67 proliferation index as a tool for chemotherapy decisions 480 during and after neoadjuvant aromatase inhibitor treatment of breast 481 cancer: Results from the American college of surgeons oncology group 482 Z1031 trial (alliance). J. Clin. Oncol. 35, 1061–1069 (2017). 483 22. Cortazar, P., Zhang, L., Untch, M., Mehta, K., Costantino, J. P., Wolmark, 484 N. et al. Pathological complete response and long-term clinical benefit in 485 486 breast cancer: The CTNeoBC pooled analysis. *Lancet* **384**, 164–172 (2014). 487

488 23. Heil, J., Kuerer, H. M., Pfob, A., Rauch, G., Sinn, H. P., Golatta, M. et al.
489 Eliminating the breast cancer surgery paradigm after neoadjuvant
490 systemic therapy: current evidence and future challenges. *Annals of*491 *Oncology* vol. 31 61–71 (2020).

- 492 24. Hortobagyi, G. N., Connolly, J. L., Orsi, C. J. D., Edge, S. B., Mittendorf,
  493 E. A., Rugo, H. S. et al. *AJCC Cancer Staging Manual 8th Edition*.
  494 *Definitions* (2020). doi:10.32388/b30ldk.
- 25. Dowsett, M., Nielsen, T. O., A'Hern, R., Bartlett, J., Coombes, R. C.,
  Cuzick, J. et al. Assessment of Ki67 in Breast Cancer: Recommendations
  from the international Ki67 in breast cancer working Group. *Journal of the National Cancer Institute* vol. 103 1656–1664 (2011).
- 499 26. Hammond, M. E. H., Hayes, D. F., Dowsett, M., Allred, D. C., Hagerty, K.
  500 L., Badve, S. et al. American Society of Clinical Oncology/College Of
  501 American Pathologists guideline recommendations for
- immunohistochemical testing of estrogen and progesterone receptors in
  breast cancer. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 28, 2784–
  2795 (2010).
- Skriver, S. K., Jensen, M. B., Knoop, A. S., Ejlertsen, B. & Laenkholm, A.
  V. Tumour-infiltrating lymphocytes and response to neoadjuvant letrozole
  in patients with early oestrogen receptor-positive breast cancer: Analysis
  from a nationwide phase II DBCG trial. *Breast Cancer Res.* 22, (2020).
- Ellis, M. J., Tao, Y., Luo, J., A'Hern, R., Evans, D. B., Bhatnagar, A. S. et
  al. Outcome prediction for estrogen receptor-positive breast cancer based
  on postneoadjuvant endocrine therapy tumor characteristics. *J. Natl. Cancer Inst.* 100, 1380–1388 (2008).
- 51329.Martí, C. & Sánchez-méndez, J. I. The present and future of neoadjuvant514endocrine therapy for breast cancer treatment. *Cancers* vol. 13 (2021).
- 30. Reis, J., Lindstrøm, J. C., Boavida, J., Gjesdal, K. I., Park, D., Bahrami, N.
  et al. Accuracy of breast MRI in patients receiving neoadjuvant endocrine
  therapy: comprehensive imaging analysis and correlation with clinical and
  pathological assessments. *Breast Cancer Res. Treat.* 184, 407–420
  (2020).

- 520 31. Fowler, A. M., Mankoff, D. A. & Joe, B. N. Imaging Neoadjuvant Therapy
- 521 Response in Breast Cancer. *Radiology* **285**, 358–375 (2017).

522

### 523 Figure legends

Figure 1. Comparison between pathological and radiological tumour size before and after neoadyuvant endocrine treatment (NET). (A-D) Correlation of pathological tumour size (path-TS) with MRI (A and C) and USS (B and D) measurements at diagnosis (A-B) and after NET (C-D). Spearman correlation coefficients (rho) and *p* values are shown. (E) Comparison of radiological tumour size (assessed by MRI and USS at diagnosis and after NET) with path-TS. *p* values were calculated using Kruskal-Wallis test.

Figure 2. Evaluation of radiological tumour response (rad-TR) after NET by 531 comparison with pathological tumour response (path-TR) and prognostic 532 biomarkers for NET. (A-B) Rad-TR was assessed by MRI (A) and USS (B) and 533 evaluated by mRECIST 1.1 criteria. Path-TR was evaluated using a modified 534 Miller and Payne grading scale. In the upper square, tumours presenting 535 complete response by MRI (A) or USS (B), but partial response (G2-G3) by 536 path-TR, are highlighted in red. (C, E and G) Analysis of Ki67 levels at surgery 537 in tumours classified according to theip values were calculated (All). (D, F and 538 H) Contingency analyses of the association between modified PEPI (mPEPI) 539 score and path-TR (D) and rad-TR by MRI (F) or USS (H). p values were 540 calculated using Kruskal-Wallis test (A-C, E, G) or Chi-square test (D, F and H). 541 CR: complete response, PR: partial response, SD: stable disease, and PD: 542 progression disease. 543

Figure 3. Tumour cellularity size (TCS) as a new parameter to measure 544 545 response to NET. (A) Comparison of radiological tumour size (assessed by MRI and USS, before and after NET) with TCS. Dotted line indicates the mean 546 547 of path-TS obtained for those tumours. (B-D) Association between TCS and pathological (path-TR) (B) and radiological response assessed by MRI (C) or 548 USS (D). (E-G) Association between TCS (E), tumour cellularity (F) and 549 pathological tumour size (path-TS) (G) with changes in Ki67 ( $\Delta$ Ki67) after NET. 550 p values were calculated using Kruskal-Wallis test. 551

552 Figure 4. Identification of a tumour cellularity size (TCS) cut-off value to 553 discriminate patients according to their response to NET. (A-B) Ki67 levels

- at surgery (A) and  $\Delta$ Ki67 (B) in tumours with low (quartile 1, Q1) versus high
- 555 (Q2, Q3 and Q4) TCS. *p* values were calculated using Mann Whitney test.





PR 49 CR 15

USS rad –TR



## Figure 4



Table 1. Histopathological information and surgical management of tumours included in our series. \*One patient was diagnosed with bilateral disease and her two tumours were independently considered in the histopathological analysis and in its surgical management. <sup>a</sup>One tumour was not evaluable for biological characteristics at surgery because the patient achieved a pCR. c/yp axillary node status was determined clinically and pathologically before and after NET, respectively. BCS: Breast-conserving surgery. N/A: not available.

Characteristics	Before NET $(n = 105^*)$	After NET (n = $104^{a}$ )
Histological grade [n (%)]	(11 100 )	(11 10+)
	23 (22)	34 (33)
II	78 (74)	69 (66)
III	4 (4)	1 (1)
Histological type [n (%)]		. ,
Ductal	86 (82)	85 (82)
Lobular	10 (10)	12 (12)
Other special type	9 (8)	7 (6)
c/yp axillary node status [n (%)]		
Negative	91 (87)	72 (69)
Positive	13 (12)	26 (25)
N/A	1 (1)	7 (6)
Positive cells (%) [mean (range)]		
Ki67	20 (3-60)	9 (0-75)
Oestrogen receptor	94 (20-100)	90 (0-99)
Progesterone receptor	63 (1-100)	15 (0-99)
Breast surgery performed [n (%)]*		
BCS		95 (90)
Modified radical mastectomy		10 (10)

Table 2. Radiological (Rad-) and pathological (Path-) tumour response (TR) after NET. Rad-TR was evaluated by mRECIST 1.1 criteria and path-TR was measured using a modified Miller and Payne grading scale. N/A: not available.

Rad-TR type [n (%)]	MRI	USS	Path-TR [n (%)]
N/A	7 (7)	14 (13)	0 (0)
Complete	27 (26)	16 (15)	1 (1)
Partial	40 (38)	49 (47)	76 (72)
Stable disease	29 (27)	24 (23)	28 (27)
Progressive disease	2 (2)	2 (2)	0 (0)